Market Overview

UPDATE: Abbott Q1 Earnings Reflect AbbVie Separation

Share:
Related ABT
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Mason Hawkins Likes Chemtura, Melco Crown; Doesn't Like Berkshire Hathaway
Complexities Of Eye Care Drive Strong Moats (Seeking Alpha)

Abbott Laboratories (NYSE: ABT) reported a 56% drop in its first-quarter earnings.

Abbott's quarterly profit fell to $544 million, or $0.34 per share, from $1.24 billion, or $0.78 per share, in the year-ago period. Excluding one-time items, its adjusted earnings from continuing operations rose to $0.42 from $0.40 per share.

Note that Q1 2012 included former proprietary pharmaceuticals business, AbbVie (NYSE: ABBV), from which Abbott Laboratories separated from on January 1, 2013.

Its net sales surged 1.8% to $5.38 billion. Abbott in January expected earnings of $0.40 to $0.42 per share.

Its operating margin widened to 11.4% from 9.7%.

Abbott shares dropped 1.10% to $36.00 in pre-market trading.

Posted-In: profitEarnings News

 

Related Articles (ABT + ABBV)

Around the Web, We're Loving...